Sánchez MR, Santin RJ, Betancourt GJR, Hurtado MR

Language: Spanish
References: 13
Page: 197-201
PDF size: 176.99 Kb.

ABSTRACT

Introduction: Bleeding is an important complication in perioperatory stage. Even most of the hemorrhages from surgical causes, an important number are defects in haemostatic failure. In this paper we discuses about bleeding due to secondary thrombocitopathy. The platelet aggregometry evaluates platelet aggregation testing 5 agonists and detects qualitative defects on aggregation. Objective: Document about mortality and morbidity of perioperator bleeding and about cost of the complications of bleeding versus platelet aggregometry in patients with bleeding history. Methods: Retrospective, lineal and descriptive study. From May 2004 to October 2005, elective surgery with bleeding history.Results: 25 patients, previous history negative for NSAID. 96% of the patients accepted automedication after bleeding episode. Non of the patients present thrombocytopenia, PT deficient in 16%, PTT in 8% and Ivy in 32%; aggregometry was abnormal in 100% of the patients. Discussion: We practice platelet aggregometry to patients with abnormal bleeding, with deficiency in 100%. These paper shows than this test its effective detecting this kind of pathology, but a clinic hystory was positive in 96%, it means that a directed interrogatory can be as effective as the aggregometry. Although aggregometry detects qualitative defects that routinely hematological test can not. Costs of hospitalizing and transfusions are grater than aggregometry. Conclusions: A directed interrogatory is the best tool for identified bleeding risk. It is pertinent to include platelet aggregometry when its indicated and evaluate to postpone surgery if is necessary.

REFERENCES

1. A tik M. A proposal for evaluation of platelet aggregation and adhesiveness for clinical trials with cyclooxygenase inhibitors and nonsteroidal anti-inflammatory drugs. J Am Coll Surg 2005; 201(2): 263-264.

2. Zhang JN, Wood J, Bergeron AL , McBride L, Ball C, Yu Q et al. Effects of low temperature on shear-induced platelet aggregation and activation. J Trauma 2004; 57(2): 216-223.

3. Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004; 15(4): 295-301.

4. G ola ski J, Nocu M, R zalski M, Drygas W, Watała C. An in vitro model for the detection of reduced platelet sensitivity to acetylsalicylic acid. Blood Coagul Fibrinolysis 2004; 15(2): 187-195.

5. Jacoby RC , Owings JT, Holmes J, Battistella FD, Gosselin RC , Paglieroni TG. Platelet activation and function after trauma. J Trauma 2001; 51(4): 639-647.

6. Patrono. Platelet-Active Drugs: The relationships among dose, effectiveness, and side effects. Chest 2001; 119(1) Supplement: 39-63.

7. White JG, Burris S, Escolar G. Influence of thrombin in suspension, surface activation, and high shear on platelet surface GPIb/IX distribution. J Lab Clin Med 1999; 133(3): 245-252.

8. Slappendel R, Weber EW, Benraad B, Dirksen R, Bugter ML. Does ibuprofen increase perioperative blood loss during hip arthroplasty? Eur J Anaesthesiol 2002; 19(11): 829-831.

9. T omassoni AJ, Simone K. Herbal medicines for children: an illusion of safety? Curr Opin Pediatr 2001; 13(2): 162-169.

10. Vane SJ. Aspirin and other anti-inflammatory drugs. Thorax 2000; 55 Suppl 2: S3-9.

11. R oberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis: implications for therapy. Anesthesiology 2004; 100(3): 722-730.

12. Bauriedel G, Skowasch D, Schneider M, Andrié R, Jabs A, Lüderitz B. Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with wholeblood aggregometry. Am Heart J 2003; 145(2): 343-348.

13. C ahill RA, McGreal GT, Crowe BH, Ryan DA, Manning BJ, Cahill MR et al. Duration of increased bleeding tendency after cessation of aspirin therapy. J Am Coll Surg 2005; 200(4): 564-573.